ForecastedResearch announcementOpportunity RFA-NS-26-030

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

National Institutes of Health · Department of Health and Human Services

At a glance

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) is a forecasted federal cooperative agreement opportunity from the National Institutes of Health (Department of Health and Human Services). The agency's forecast estimates an application due date of November 10, 2026; forecast dates can change. Total estimated funding is $6M across about 3 awards. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Feb 12, 2026Forecast posted
Jul 1, 2026 (est.)Full notice expected
Nov 10, 2026 (est.)Application deadlinenext date
Jul 1, 2027 (est.)Est. award date

Posted: Feb 12, 2026
Est. close date: Nov 10, 2026
Est. award date: Jul 1, 2027
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: $6,000,000
Implied average award: $2,000,000 calculated
Expected awards: 3
Cost sharing: Not required
Funding instrument: Cooperative Agreement
Opportunity category: Discretionary
Fiscal year: FY2027

Typical awards for this program (SAM.gov listing for ALN 93.853, not this notice): Research grants: $22,709 to $7,753,905; $585,282. National Research Service Awards: Institutional $34,076 to $692,757; $193,304. Individual: $5,495 to $90,284; $46,239. SBIR/STTR: Phase 1 not to exceed $150,000; Phase II not to exceed $1,000,000; however with appropriate justification, budget caps for Phase I and Phase II are $225,000 and $1,500,00 respectively

Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.

Who can apply

State governments
County governments
City or township governments
Special district governments
Independent school districts
Public colleges & universities
Federally recognized tribal governments
Public & Indian housing authorities
Native American tribal organizations
501(c)(3) nonprofits
Nonprofits without 501(c)(3) status
Private colleges & universities
For-profit organizations (not small businesses)
Small businesses
Others (see notice)

Additional information on eligibility (from the notice)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing.

This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may include activities to refine therapeutic design and manufacturability; establish pharmacology, toxicology, biodistribution, and in vivo efficacy; to generate the full body of data required to support regulatory interactions and IND submissions, and, when appropriate, first-in-human (FIH) clinical studies.

The program is aligned with priorities from the ADRD Summits, including acceleration of disease-modifying therapeutic development in frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular contributions to cognitive impairment and dementia (VCID). Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

How to apply

0 of 8 done · progress saved in this browser

Read the full announcement (NOFO)Eligibility, evaluation criteria, page limits and required attachments are in the full notice on Grants.gov. Open ↗
Confirm eligibility and fitCheck your organization type above; no cost sharing is required.
Register (or renew) in SAM.gov and get a UEIFree. New registrations can take several weeks; registrations must be renewed every year. Open ↗
Set up Grants.gov accessCreate a Grants.gov account and make sure someone has the Authorized Organization Representative (AOR) role. Open ↗
Watch for the full noticeThe agency estimates posting it around July 1, 2026. Save this grant to track changes.
Prepare narrative, budget and attachmentsFollow the notice's format exactly — page limits and required forms are common reasons applications are rejected.
Ask the agency contact any questions earlyNINDS ADRD Program · nindsdonadrd@mail.nih.gov Open ↗
Submit before November 10, 2026Submit a few days early and keep your Grants.gov confirmation and validation emails.

Assistance Listing

What is an ALN?

93.853Extramural Research Programs in the Neurosciences and Neurological DisordersProgram →

Reported obligations under ALN 93.853

Historical data · not a prediction

FY24

$2.36B

FY25

$2.35B

FY26

— est.

Source: SAM.gov Assistance Listing 93.853. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

NINDS ADRD Program
nindsdonadrd@mail.nih.gov
Please contact via e-mail

Quick answers

Is “Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)” open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around July 1, 2026. Forecast details and dates can change.

Who is eligible to apply for “Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)”?

The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How much funding is available through “Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)”?

Per the notice, total estimated program funding is $6,000,000 and the agency expects to make about 3 awards.

How do I apply for “Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-NS-26-030), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

ForecastedResearchALN 93.853